As filed with the Securities and Exchange Commission on August 6, 2026

 

Registration No. 333-

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

 

 

NOVAVAX, INC.

(Exact name of Registrant as specified in its charter)

 

Delaware

21 Firstfield Road,

Gaithersburg, Maryland 20878

22-2816046
(State of incorporation) (Address of principal executive offices) (I.R.S. Employer Identification No.)

 

 

Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan

Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan

(Full Title of the Plan)

 

Mark J. Casey

Executive Vice President, Chief Legal Officer & Corporate Secretary

Novavax, Inc.

21 Firstfield Road

Gaithersburg, Maryland 20878

(240) 268-2000

(Name, Address and Telephone Number, Including Area Code, of Agent For Service)

 

with copies to:

Wesley C. Holmes

Elisabeth M. Martin

Latham & Watkins LLP

200 Clarendon Street

Boston, Massachusetts 02116

(617) 880-4500

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer x Accelerated filer ¨
Non-accelerated filer ¨ Smaller reporting company ¨
  Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed for the purpose of registering (i) 1,310,300 additional shares of common stock, par value $0.01 per share (the “Common Stock”), of Novavax, Inc. (the “Registrant”) that may be issued and sold pursuant to the Registrant’s Amended and Restated 2013 Employee Stock Purchase Plan, as amended (the “2013 Plan”), and (ii) 9,400,000 additional shares of Common Stock that may be issued pursuant to awards under the Registrant’s Amended and Restated 2015 Stock Incentive Plan (the “2015 Plan”), for which prior Registration Statements on Form S-8 (File Nos. 333-190599, 333-206354, 333-213069,333-219829, 333-226498, 333-233133, 333-243758, 333-258517, 333-266681, 333-273791 and 333-281376) are effective.

 

Pursuant to General Instruction E of Form S-8, the contents of the above referenced prior Registration Statements on Form S-8, including any amendments thereto, filed with the Securities and Exchange Commission, relating to the 2013 Plan and the 2015 Plan are incorporated herein by reference.

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

  

Item 8. Exhibits.

 

INDEX OF EXHIBITS

 

Exhibit    
Number   Description 
4.1   Second Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10, 2015)
4.2   Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 9, 2019)
4.3   Certificate of Designation of Series A Convertible Preferred Stock of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 19, 2020)
4.4   Amended and Restated By-Laws of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on April 26, 2024)
5.1*   Opinion of Latham & Watkins  LLP
23.1*   Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
23.2*   Consent of Latham & Watkins LLP (included in Exhibit 5.1)
24.1*   Power of Attorney (included on the signature pages)
99.1   Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed on August 6, 2026)
99.2   Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed on August 6, 2026)
107.1*   Filing Fee Table

 

  * Filed herewith

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Gaithersburg, state of Maryland on August 6, 2026.

 

NOVAVAX, INC.  
   
By: /s/ John C. Jacobs  
  John C. Jacobs  
  President and Chief Executive Officer  

 

POWER OF ATTORNEY

 

Each person whose signature appears below constitutes and appoints John C. Jacobs, James P. Kelly and Mark J. Casey, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Novavax, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature    Title    Date 
         
/s/ John C. Jacobs   President and Chief Executive Officer   August 6, 2026
John C. Jacobs   and Director (Principal Executive Officer)    
         
/s/ James P. Kelly   Executive Vice President, Chief Financial Officer   August 6, 2026
James P. Kelly   and Treasurer (Principal Financial and Accounting Officer)    
         
/s/ David M. Mott   Chairman of the Board of Directors   August 6, 2026
David M. Mott        
         
/s/ Gregg H. Alton   Director   August 6, 2026
Gregg H. Alton        
         
/s/ Richard H. Douglas   Director   August 6, 2026
Richard H. Douglas        
         
/s/ Rachel K. King   Director   August 6, 2026
Rachel K. King        
         
/s/ Margaret G. McGlynn   Director   August 6, 2026
Margaret G. McGlynn        
         
/s/ Charles W. Newton   Director   August 6, 2026
Charles W. Newton        
         
/s/ Richard J. Rodgers   Director   August 6, 2026
Richard J. Rodgers        
         
/s/ John W. Shiver, Ph.D.   Director   August 6, 2026
John W. Shiver, Ph.D.        

 

 

 

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EXHIBIT 5.1

EXHIBIT 23.1

EX-FILING FEES

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: tm2622319d1_ex-filingfees_htm.xml